10:31 ETFood Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsightprnewswire·2 days ago, 09:32 AMNVS-0.64%RAPT0.00%
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data UpsideTip Ranks·May 18 at 06:05 PMRAPT0.00%
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Sharenasdaq·Mar 15 at 05:35 PMXBI-1.25%GSK-0.91%
Rapt Therapeutics (NASDAQ:RAPT) Receives Average Rating of "Hold" from AnalystsMarket Beat·Mar 5 at 12:44 AMVHT-0.61%XBI-1.25%
RAPT Therapeutics Completes Acquisition and Transitions to Private OwnershipTip Ranks·Mar 3 at 08:37 AMIHE-0.44%IBB-1.04%
Rapt Therapeutics (NASDAQ:RAPT) Sees Large Growth in Short InterestMarket Beat·Feb 13 at 08:41 AMRAPT0.00%SBIO-0.60%
20:02 ETAre RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?prnewswire·Feb 11 at 07:03 PMLSTA-6.03%AVO+0.16%
Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from AnalystsMarket Beat·Feb 8 at 01:38 AMXLV-0.61%VHT-0.61%
Halper Sadeh LLC investigates possible unfair pricing for NWE, DHIL, RAPT shares, offering free consultations to concerned shareholders.Unusual Whales·Feb 6 at 03:32 PMNWE-2.32%SBIO-0.60%
16:29 ETHalper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholdersprnewswire·Feb 6 at 03:30 PMDHIL0.00%RAPT0.00%
